{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:09:52Z","timestamp":1793815792405,"version":"4.6.1"},"reference-count":140,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:00:00Z","timestamp":1538697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oooojournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.oooo.2018.09.008","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:24:02Z","timestamp":1539044642000},"page":"117-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":310,"title":["Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment"],"prefix":"10.1016","volume":"127","author":[{"given":"Ourania","family":"Nicolatou-Galitis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schi\u00f8dt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7628-8598","authenticated-orcid":false,"given":"Rui Amaral","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Ripamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Drudge-Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Niepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Van den Wyngaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oooo.2018.09.008_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.oooo.2018.09.008_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4081\/reumatismo.2017.983","article-title":"Drug-induced osteonecrosis of the jaw: the state of the art","volume":"69","author":"Fassio","year":"2017","journal-title":"Reumatismo"},{"key":"10.1016\/j.oooo.2018.09.008_bib0003","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bjoms.2014.09.001","article-title":"Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed","volume":"53","author":"Fedele","year":"2015","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.09.008_bib0004","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.oooo.2013.10.010","article-title":"Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system","volume":"117","author":"Schiodt","year":"2014","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0005","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1601-0825.2012.01911.x","article-title":"Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines","volume":"18","author":"Patel","year":"2012","journal-title":"Oral Dis"},{"key":"10.1016\/j.oooo.2018.09.008_bib0006","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1345\/aph.1M102","article-title":"Denosumab in osteoporosis and oncology","volume":"43","author":"Burkiewicz","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.oooo.2018.09.008_bib0007","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0008","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.oooo.2018.09.008_bib0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.oooo.2018.09.008_bib0012","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00228-017-2210-x","article-title":"Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review","volume":"73","author":"de Boissieu","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0013","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","article-title":"Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ","volume":"20","author":"Khan","year":"2017","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.oooo.2018.09.008_bib0014","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"(Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Pamidronate","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.09.008_bib0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bjoms.2009.08.030","article-title":"Osteonecrosis of the jaws induced by anti-RANK ligand therapy","volume":"48","author":"Taylor","year":"2010","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.09.008_bib0016","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.joms.2009.10.010","article-title":"Osteonecrosis of the jaw in a patient on denosumab","volume":"68","author":"Aghaloo","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.09.008_bib0017","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0018","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0019","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.bdj.2015.680","article-title":"New cancer therapies and jaw necrosis","volume":"219","author":"Patel","year":"2015","journal-title":"Br Dent J"},{"key":"10.1016\/j.oooo.2018.09.008_bib0020","doi-asserted-by":"crossref","DOI":"10.5301\/tj.5000405","article-title":"Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district","volume":"102","author":"Ponzetti","year":"2016","journal-title":"Tumori"},{"key":"10.1016\/j.oooo.2018.09.008_bib0021","doi-asserted-by":"crossref","first-page":"220","DOI":"10.20517\/2394-4722.2016.06","article-title":"Osteonecrosis of the jaw in a patient with acute myeloid leukemia, who received azacitidine","volume":"2","author":"Nicolatou-Galitis","year":"2016","journal-title":"J Cancer Metastasis Treat"},{"key":"10.1016\/j.oooo.2018.09.008_bib0022","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.oraloncology.2011.07.030","article-title":"A case report of bevacizumab-related osteonecrosis of the jaw: Old problem, new culprit","volume":"48","author":"Disel","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0023","first-page":"1793","article-title":"Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: An uncommon but potentially severe disease","volume":"33","author":"Sivolella","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.oooo.2018.09.008_bib0024","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5125\/jkaoms.2017.43.2.120","article-title":"A rare case of osteonecrosis of the jaw related to imatinib","volume":"43","author":"Viviano","year":"2017","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.09.008_bib0025","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/j.bjoms.2013.09.008","article-title":"Osteonecrosis of the jaw related to everolimus: a case report","volume":"51","author":"Kim","year":"2013","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.09.008_bib0026","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcms.2013.05.014","article-title":"Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab","volume":"42","author":"Allegra","year":"2014","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.oooo.2018.09.008_bib0027","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/j.oraloncology.2015.08.014","article-title":"Osteonecrosis of the jaw a new complication related to ipilimumab","volume":"51","author":"Owosho","year":"2015","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0028","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.oooo.2018.09.008_bib0029","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.09.008_bib0030","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"J Am Dent Assoc"},{"issue":"862","key":"10.1016\/j.oooo.2018.09.008_bib0031","first-page":"e861","article-title":"Western Osteoporosis Alliance Clinical Practice Series: evaluating the balance of benefits and risks of long-term osteoporosis therapies","volume":"130","author":"Hanley","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.oooo.2018.09.008_bib0032","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8768162","article-title":"Medication-related osteonecrosis of the jaw: new insights into molecular mechanisms and cellular therapeutic approaches","volume":"2016","author":"Lombard","year":"2016","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.oooo.2018.09.008_bib0033","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/jcpe.12455","article-title":"Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis","volume":"42","author":"Gaudin","year":"2015","journal-title":"J Clin Periodontol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0034","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.oooo.2016.11.011","article-title":"Bacterial diversity in medication-related osteonecrosis of the jaw","volume":"123","author":"Hallmer","year":"2017","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0035","series-title":"Medication-Related Osteonecrosis of the Jaws","author":"Otto","year":"2015"},{"key":"10.1016\/j.oooo.2018.09.008_bib0036","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.joms.2013.02.016","article-title":"Oral health risk factors for bisphosphonate-associated jaw osteonecrosis","volume":"71","author":"Tsao","year":"2013","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.09.008_bib0037","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.ijom.2013.06.011","article-title":"Bacterial promotion of bisphosphonate-induced osteonecrosis in Wistar rats","volume":"42","author":"Tsurushima","year":"2013","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.09.008_bib0038","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.oooo.2015.08.007","article-title":"Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review","volume":"120","author":"Nicolatou-Galitis","year":"2015","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0039","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2016.70.7257","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Dhesy-Thind","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0040","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/sj.bdj.2017.79","article-title":"Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners","volume":"222","author":"Tanna","year":"2017","journal-title":"Br Dent J"},{"key":"10.1016\/j.oooo.2018.09.008_bib0042","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/pcan.2016.62","article-title":"Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials","volume":"20","author":"Saad","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.oooo.2018.09.008_bib0043","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1007\/s00198-017-4110-4","article-title":"Estimating the long-term functional burden of osteoporosis-related fractures","volume":"28","author":"Fischer","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.oooo.2018.09.008_bib0044","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1007\/s00198-016-3620-9","article-title":"The impact of osteoporotic fractures compared with other health conditions in older adults living in Virginia, United States","volume":"27","author":"Cunningham","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.oooo.2018.09.008_bib0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5312\/wjo.v7.i3.171","article-title":"Major osteoporotic fragility fractures: risk factor updates and societal impact","volume":"7","author":"Pisani","year":"2016","journal-title":"World J Orthop"},{"key":"10.1016\/j.oooo.2018.09.008_bib0046","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.oooo.2018.09.008_bib0047","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","article-title":"An overview and management of osteoporosis","volume":"4","author":"Sozen","year":"2017","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0048","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","article-title":"Meta-analysis: excess mortality after hip fracture among older women and men","volume":"152","author":"Haentjens","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.oooo.2018.09.008_bib0049","doi-asserted-by":"crossref","first-page":"37","DOI":"10.11005\/jbm.2017.24.1.37","article-title":"The efficacy of bisphosphonates for prevention of osteoporotic fracture: an update meta-analysis","volume":"24","author":"Byun","year":"2017","journal-title":"J Bone Metab"},{"key":"10.1016\/j.oooo.2018.09.008_bib0050","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1517\/17425255.2015.1000860","article-title":"Denosumab for the treatment of osteoporosis","volume":"11","author":"Zaheer","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0051","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0052","first-page":"814","article-title":"Medication selection and patient compliance in the clinical management of osteoporosis","volume":"45","author":"Inderjeeth","year":"2016","journal-title":"Aust Fam Physician"},{"key":"10.1016\/j.oooo.2018.09.008_bib0053","first-page":"56","article-title":"Cost and consequences of noncompliance to oral bisphosphonate treatment","volume":"21","author":"Eisenberg","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.oooo.2018.09.008_bib0054","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00198-015-3164-4","article-title":"Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study","volume":"26","author":"Hadji","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.oooo.2018.09.008_bib0055","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11657-016-0282-3","article-title":"Persistence with denosumab and zoledronic acid among older women: a population-based cohort study","volume":"11","author":"Tremblay","year":"2016","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.oooo.2018.09.008_bib0056","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.oooo.2018.09.008_bib0059","author":"Chilcott"},{"key":"10.1016\/j.oooo.2018.09.008_bib0061","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ctrv.2015.09.003","article-title":"Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications","volume":"41","author":"D'Oronzo","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.oooo.2018.09.008_bib0062","first-page":"116","article-title":"Prevention and treatment of bone fragility in cancer patient","volume":"12","author":"Ottanelli","year":"2015","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.oooo.2018.09.008_bib0063","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.oooo.2018.09.008_bib0064","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/pcan.2011.4","article-title":"Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis","volume":"15","author":"Serpa Neto","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.oooo.2018.09.008_bib0065","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oooo.2018.09.008_bib0066","first-page":"321","article-title":"Bone metastases: an overview","volume":"11","author":"Macedo","year":"2017","journal-title":"Oncol Rev"},{"key":"10.1016\/j.oooo.2018.09.008_bib0067","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.oooo.2018.09.008_bib0068","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.oooo.2018.09.008_bib0069","first-page":"1327","article-title":"Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases","volume":"24","author":"von Moos","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.oooo.2018.09.008_bib0070","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/pcan.2017.4","article-title":"Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases","volume":"20","author":"McKay","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.oooo.2018.09.008_bib0071","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jbo.2014.04.001","article-title":"Health resource utilization associated with skeletal-related events in patients with bone metastases: results from a multinational retrospective-prospective observational study\u2014a cohort from 4 European countries","volume":"3","author":"Hoefeler","year":"2014","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0072","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10198-015-0716-7","article-title":"Health resource utilization associated with skeletal-related events: results from a retrospective European study","volume":"17","author":"Body","year":"2016","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.oooo.2018.09.008_bib0073","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0074","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0075","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3816\/CGC.2002.n.016","article-title":"Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone","volume":"1","author":"Saad","year":"2002","journal-title":"Clin Prostate Cancer"},{"key":"10.1016\/j.oooo.2018.09.008_bib0076","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.oooo.2018.09.008_bib0077","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0084","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12094-014-1268-5","article-title":"Giant cell tumour of bone: new treatments in development","volume":"17","author":"Lopez-Pousa","year":"2015","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0085","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1148\/rg.331125089","article-title":"Giant cell tumor of bone: review, mimics, and new developments in treatment","volume":"33","author":"Chakarun","year":"2013","journal-title":"Radiographics"},{"key":"10.1016\/j.oooo.2018.09.008_bib0086","article-title":"Denosumab therapy for giant cell tumor of bone pulmonary metastasis","volume":"2017","author":"Egbert","year":"2017","journal-title":"Case Rep Orthop"},{"key":"10.1016\/j.oooo.2018.09.008_bib0087","first-page":"3795","article-title":"Functional results after giant cell tumor operation near knee joint and the cement radiolucent zone as indicator of recurrence","volume":"30","author":"Kafchitsas","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.oooo.2018.09.008_bib0088","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0089","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-12-0578","article-title":"Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone","volume":"18","author":"Branstetter","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.oooo.2018.09.008_bib0090","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3109\/0284186X.2014.910313","article-title":"Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study","volume":"53","author":"Martin-Broto","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0091","doi-asserted-by":"crossref","first-page":"V605","DOI":"10.1093\/annonc\/mdx440.071","article-title":"Long-term efficacy of denosumab in giant cell tumor of bone: results of an open-label phase 2 study","volume":"28","author":"Palmerini","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0092","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4103\/1947-2714.170600","article-title":"Hypercalcemia of malignancy: an update on pathogenesis and management","volume":"7","author":"Mirrakhimov","year":"2015","journal-title":"N Am J Med Sci"},{"key":"10.1016\/j.oooo.2018.09.008_bib0093","first-page":"1779","article-title":"Hypercalcemia of malignancy and new treatment options","volume":"11","author":"Sternlicht","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.oooo.2018.09.008_bib0094","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0095","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2014-1001","article-title":"Denosumab for treatment of hypercalcemia of malignancy","volume":"99","author":"Hu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.oooo.2018.09.008_bib0096","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2147\/TCRM.S58367","article-title":"Current perspectives on bisphosphonate treatment in Paget's disease of bone","volume":"10","author":"Wat","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.oooo.2018.09.008_bib0098","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s00223-016-0150-6","article-title":"Treatment of Paget's disease of bone with denosumab: case report and literature review","volume":"99","author":"Reid","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.oooo.2018.09.008_bib0099","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/jbmr.2058","article-title":"Renal safety in patients treated with bisphosphonates for osteoporosis: a review","volume":"28","author":"Miller","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.oooo.2018.09.008_bib0100","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1378\/chest.13-0675","article-title":"Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis","volume":"144","author":"Sharma","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.oooo.2018.09.008_bib0101","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/joim.12339","article-title":"Efficacy, effectiveness and side effects of medications used to prevent fractures","volume":"277","author":"Reid","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.oooo.2018.09.008_bib0102","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.oooo.2018.09.008_bib0103","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1159\/000447372","article-title":"Safety of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials","volume":"39","author":"Chen","year":"2016","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.oooo.2018.09.008_bib0104","first-page":"447","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.oooo.2018.09.008_bib0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/DHPS.S6285","article-title":"Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management","volume":"2","author":"Dalle Carbonare","year":"2010","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.oooo.2018.09.008_bib0106","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/ajco.12517","article-title":"Denosumab: prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures","volume":"13","author":"Pittman","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0107","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1159\/000343950","article-title":"Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation","volume":"35","author":"Then","year":"2012","journal-title":"Onkologie"},{"key":"10.1016\/j.oooo.2018.09.008_bib0108","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/1471-2474-12-209","article-title":"The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women","volume":"12","author":"Hopkins","year":"2011","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.oooo.2018.09.008_bib0109","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.oooo.2018.09.008_bib0110","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.oooo.2018.09.008_bib0111","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.oooo.2018.09.008_bib0112","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.oooo.2018.09.008_bib0113","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0114","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.oooo.2018.09.008_bib0115","first-page":"S21","article-title":"Localized alveolar bone disease before dental extraction in cancer patients treated with antiresorptives: an early stage of osteonecrosis of the jaw (ONJ)","volume":"25","author":"Papadopoulou","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.oooo.2018.09.008_bib0116","series-title":"Antiresorptive Drug-Related Osteonecrosis of the Jaw (ARONJ)\u2014A Guide to Research","first-page":"40","author":"Fleisher","year":"2016"},{"key":"10.1016\/j.oooo.2018.09.008_bib0117","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcms.2015.03.039","article-title":"Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development?","volume":"43","author":"Otto","year":"2015","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.oooo.2018.09.008_bib0118","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jcms.2016.09.018","article-title":"Clinical features of peri-implant medication-related osteonecrosis of the jaw: is there an association to peri-implantitis?","volume":"44","author":"Troeltzsch","year":"2016","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.oooo.2018.09.008_bib0119","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.oooo.2017.11.022","article-title":"Microbial population changes in patients with medication-related osteonecrosis of the jaw treated with systemic antibiotics","volume":"125","author":"De Bruyn","year":"2017","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/2231-0762.178742","article-title":"Medication-related osteonecrosis of the jaw: clinical and practical guidelines","volume":"6","author":"Rosella","year":"2016","journal-title":"J Int Soc Prev Community Dent"},{"key":"10.1016\/j.oooo.2018.09.008_bib0121","first-page":"869","article-title":"Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"26","author":"van Cann","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.oooo.2018.09.008_bib0122","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oooo.2018.09.008_bib0123","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00198-015-3335-3","article-title":"Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015","volume":"27","author":"Khan","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.oooo.2018.09.008_bib0124","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.oooo.2018.09.008_bib0125","series-title":"Oral and Maxillofacial Pathology","author":"Neville","year":"2016"},{"key":"10.1016\/j.oooo.2018.09.008_bib0126","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00784-017-2325-6","article-title":"Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol","volume":"22","author":"Ramaglia","year":"2018","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.oooo.2018.09.008_bib0127","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s00198-017-4063-7","article-title":"A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?","volume":"28","author":"Hasegawa","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.oooo.2018.09.008_bib0128","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","volume":"68","author":"Lo","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.09.008_bib0131","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1185\/03007995.2016.1170005","article-title":"Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw","volume":"32","author":"Taguchi","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.oooo.2018.09.008_bib0132","doi-asserted-by":"crossref","first-page":"117","DOI":"10.7257\/1053-816X.2016.36.3.117","article-title":"Retrospective audit: Does prior assessment by oral and maxillofacial surgeons reduce the risk of osteonecrosis of the jaw in patients receiving bone-targeted therapies for metastatic cancers to the skeleton? Part II","volume":"36","author":"Turner","year":"2016","journal-title":"Urol Nurs"},{"key":"10.1016\/j.oooo.2018.09.008_bib0133","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijom.2017.02.399","article-title":"Risk of osteonecrosis of the jaws after tooth extraction of 270 teeth with alveolectomy and primary surgical closure in 111 patients on antiresorptive treatment","volume":"46","author":"Schiodt","year":"2017","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.09.008_bib0134","first-page":"e141","article-title":"Prophylaxis and antibiotic therapy in management protocols of patients treated with oral and intravenous bisphosphonates","volume":"9","author":"Bermudez-Bejarano","year":"2017","journal-title":"J Clin Exp Dent"},{"key":"10.1016\/j.oooo.2018.09.008_bib0135","series-title":"Dental Emergencies","first-page":"217","article-title":"Protocol for surgical dental treatment of patients taking bisphosphonates","author":"Greenwood","year":"2013"},{"key":"10.1016\/j.oooo.2018.09.008_bib0136","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3109\/00016357.2014.887772","article-title":"Characteristics of the early stages of intravenous bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer","volume":"72","author":"Matsuo","year":"2014","journal-title":"Acta Odontol Scand"},{"key":"10.1016\/j.oooo.2018.09.008_bib0137","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1601-0825.2012.01903.x","article-title":"Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ)","volume":"18","author":"Bedogni","year":"2012","journal-title":"Oral Dis"},{"key":"10.1016\/j.oooo.2018.09.008_bib0138","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.amjmed.2010.04.033","article-title":"Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series","volume":"123","author":"Fedele","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.oooo.2018.09.008_bib0139","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejon.2011.02.006","article-title":"Taking the lead: sharing best practice in intravenous bisphosphonate use in urologic cancers","volume":"16","author":"Jensen","year":"2012","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.oooo.2018.09.008_bib0140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.joms.2014.07.012","article-title":"Temporal correlation between bisphosphonate termination and symptom resolution in osteonecrosis of the jaw: a pooled case report analysis","volume":"73","author":"Hinson","year":"2015","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.09.008_bib0141","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.oraloncology.2011.02.024","article-title":"Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis","volume":"47","author":"Bedogni","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0142","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tripleo.2010.04.015","article-title":"The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw","volume":"111","author":"Wilde","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.oooo.2018.09.008_bib0143","first-page":"1905","article-title":"A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer","volume":"26","author":"Schiodt","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.oooo.2018.09.008_bib0144","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.oraloncology.2011.01.002","article-title":"Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: preliminary results of a phase I-II study","volume":"47","author":"Ripamonti","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0145","first-page":"807","article-title":"The effect of laser therapy on the expression of osteocalcin and osteopontin after tooth extraction in rats treated with zoledronate and dexamethasone","volume":"24","author":"Mergoni","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.oooo.2018.09.008_bib0146","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2018.ed77","article-title":"Osteonecrosis of the jaw (ONJ) in patients who receive Bone Targeting Agents (BTAs): the power of e-learning","volume":"12","author":"Nicolatou-Galitis","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.oooo.2018.09.008_bib0147","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/dj5010013","article-title":"Osteonecrosis of the Jaw (ONJ) in osteoporosis patients: report of delayed diagnosis of a multisite case and commentary about risks coming from a restricted ONJ definition","volume":"5","author":"Migliario","year":"2017","journal-title":"J Dent"},{"key":"10.1016\/j.oooo.2018.09.008_bib0148","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.bjoms.2014.04.009","article-title":"Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease","volume":"52","author":"Bedogni","year":"2014","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.09.008_bib0149","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.oraloncology.2014.08.016","article-title":"A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ)","volume":"50","author":"Rupel","year":"2014","journal-title":"Oral Oncol"},{"key":"10.1016\/j.oooo.2018.09.008_bib0150","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijom.2015.01.026","article-title":"Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review","volume":"44","author":"Fliefel","year":"2015","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.09.008_bib0151","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8071579","article-title":"Osteonecrosis of the jaw associated with antiangiogenics in antiresorptive-naive patient: a comprehensive review of the literature","volume":"2018","author":"Pimolbutr","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.oooo.2018.09.008_bib0152","first-page":"S39","article-title":"Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review","volume":"26","author":"Nicolatou-Galitis","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.oooo.2018.09.008_bib0153","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1634\/theoncologist.2010-0183","article-title":"Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw","volume":"16","author":"Miksad","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.oooo.2018.09.008_bib0154","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40271-015-0158-4","article-title":"Patient, caregiver, and nurse preferences for treatments for bone metastases from solid tumors","volume":"9","author":"Qian","year":"2016","journal-title":"Patient"},{"key":"10.1016\/j.oooo.2018.09.008_bib0155","first-page":"21","article-title":"Patients\u2019 preferences for bone metastases treatments in France, Germany and the United Kingdom","volume":"23","author":"Hechmati","year":"2015","journal-title":"Support Care Cancer"}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440318311933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440318311933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:02:10Z","timestamp":1761948130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212440318311933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":140,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S2212440318311933"],"URL":"https:\/\/doi.org\/10.1016\/j.oooo.2018.09.008","relation":{},"ISSN":["2212-4403"],"issn-type":[{"value":"2212-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment","name":"articletitle","label":"Article Title"},{"value":"Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oooo.2018.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}